Skip to main contentAI and Advanced
/
PANACEABIO · NSEBSE SENSEX77,472.94-0.24%BSE |
NIFTY 5024,207.75-0.52%NSE |
NIFTY BANK57,783.75+0.47%NSE |
NIFTY IT30,318.85-1.47%NSE |
NIFTY AUTO29,000.15-0.74%NSE |
NIFTY FMCG47,252.9-0.95%NSE |
NIFTY PHARMA26,626.3+0.23%NSE |
NIFTY 50023,559.2-0.22%NSE |
PA
NSE · Equity shares · Biotechnology & Drugs-10.80 · -2.64%
Panacea Biotec PANACEABIO
NSE:INR 398
BSE:INR 466.05
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for PANACEABIO
Analysis, reports, chat and Advanced access use the same ShareKeyX account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 408.8
Day rangeINR 395 — INR 410.05
52-week rangeINR 292.4 — INR 647
Volume81,708
Market cap2,811.95
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)639.77
Net Income (INR Cr)-5.37
Rev Growth (5 Year %)0.47
Book Value127.99
EPS-2.96
Price/BV3.11Computed
Research path: Interpret Panacea Biotec's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
PANACEABIOPanacea Biotec1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,262.17 | 1,289.75 | 1,240.67 |
| Cash Equivalents | 7.06 | 30.94 | 6.5 |
| Other Liabilities Total | 37.81 | 46.65 | 50.08 |
| Common Stock Total | 6.13 | 6.13 | 6.13 |
| Other Current Assets Total | 110.13 | 32.96 | 33.58 |
| Total Assets | 1,262.17 | 1,289.75 | 1,240.67 |
| Current Portof LT Debt/Capital Leases | 23.66 | 0 | 0 |
| Cash | 57.31 | 51.19 | 40.67 |
| Total Equity | 834.84 | 834.79 | 842.05 |
| Long Term Investments | 27.53 | 15.91 | 12.76 |
| Retained Earnings(Accumulated Deficit) | 828.71 | 729.83 | 738.26 |
| Total Common Shares Outstanding | 6.13 | 6.13 | 6.13 |
| Tangible Book Valueper Share Common Eq | 127.99 | 129.39 | 131.6 |
| Total Liabilities | 427.33 | 454.96 | 398.63 |
| Total Debt | 23.66 | 22.21 | 20.99 |
| Short Term Investments | 70.29 | 64.04 | 104.27 |
| Cashand Short Term Investments | 134.66 | 146.16 | 151.44 |
| Total Receivables Net | 75.46 | 138.36 | 111.36 |
| Deferred Income Tax | 23.14 | 23.28 | 22.54 |
| Accounts Receivable-Trade Net | 73.52 | 72.56 | 57.42 |
| Property/Plant/Equipment Total-Net | 653.24 | 636.9 | 634.76 |
| Minority Interest | -5.96 | -4.17 | -3.82 |
| Total Current Liabilities | 372.34 | 366.99 | 308.83 |
| Total Inventory | 192.79 | 220.58 | 182.74 |
| Total Preferred Shares Outstanding | 1.61 | 1.61 | 1.61 |
| Accounts Payable | 189.6 | 225.76 | 153.68 |
| Other Currentliabilities Total | 159.08 | 129.79 | 144.97 |
| Intangibles Net | 50.89 | 42.26 | 36 |
| Other Long Term Assets Total | 1.22 | 6.05 | 3.03 |
| Note Receivable-Long Term | 16.25 | 43.44 | 68.95 |
| Total Current Assets | 513.04 | 545.18 | 485.18 |
| Accumulated Depreciation Total | Not available | -687.91 | -656.22 |
| Accrued Expenses | Not available | 11.45 | 10.18 |
| Long Term Debt | Not available | 22.21 | 20.99 |
| Other Equity Total | Not available | 6.89 | 5.72 |
| Prepaid Expenses | Not available | 7.11 | 6.06 |
| Additional Paid-In Capital | Not available | 91.94 | 91.94 |
| Property/Plant/Equipment Total-Gross | Not available | 1,231.3 | 1,216.26 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
| Total Long Term Debt | Not available | 22.21 | 20.99 |
Fundamentals
Valuation and ratios
Growth
Debt 5Yr CAGR %-50.79
Margins
Operating Margin 12m-2.85
Operating Margin 5y Avg54.3
Net Profit Margin 12m-1.12
Net Profit Margin 5y35.66
Yield
Dividend Yield %0
Valuation
Price to Sale Ratio4.40
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk60.44
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,938.25 | 4.65 L | 38.4 | — |
| Divi's Laboratories | INR 7,365.5 | 1.96 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,982.45 | 1.69 L | 72.73 | — |
| Cipla | INR 1,410.1 | 1.14 L | 27.57 | — |
| Zydus Lifesciences | INR 1,120.35 | 1.12 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 72.48%
- FII
- 2.31%
- Other
- 25.21%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals - Markets MojoMarket news · 2 Jun 2026, 7:49 pm
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals Markets Mojo
Panacea Biotec Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks - Markets MojoMarket news · 2 Jun 2026, 3:56 pm
Panacea Biotec Ltd Downgraded to Strong Sell Amid Weak Fundamentals and Technical Setbacks Markets Mojo
Panacea Biotec Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals - Markets MojoMarket news · 2 Jun 2026, 10:02 am
Panacea Biotec Downgraded to Strong Sell Amid Weak Fundamentals and Bearish Technicals Markets Mojo
Panacea Biotec Q4 FY26: Losses Return as Operating Margins Collapse Despite Revenue Growth - Markets MojoMarket news · 1 Jun 2026, 10:18 pm
Panacea Biotec Q4 FY26: Losses Return as Operating Margins Collapse Despite Revenue Growth Markets Mojo
Panacea Biotec narrows FY26 loss, passes over dividend - scanx.tradeMarket news · 1 Jun 2026, 12:30 pm
Panacea Biotec narrows FY26 loss, passes over dividend scanx.trade
Panacea Biotec reports consolidated net profit of Rs 0.52 crore in the March 2026 quarter - Business StandardMarket news · 1 Jun 2026, 11:18 am
Panacea Biotec reports consolidated net profit of Rs 0.52 crore in the March 2026 quarter Business Standard
Corporate actions
Events
- board MeetingsAudited Results & Dividend
- board MeetingsAudited Results & Dividend
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
- board MeetingsAudited Results & Dividend
- annual General MeetingPOM
ShareKeyX Community
Discussion and sentiment for Panacea Biotec
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and ShareKeyX AI.
Checking your ShareKeyX account…
Company profile
Business information
What the company does
Panacea Biotec Limited is an India-based pharmaceutical and biotechnology company with research, manufacturing and marketing capabilities. The Company is engaged in the business of research, development, manufacture and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals and food and nutrition products in India and international markets. Its segments include vaccines and pharmaceutical formulations and nutrition. Panacea Biotec specializes in complex generics, vaccines, and novel drug delivery platforms. Its vaccine portfolio includes EasySix (DTwP-Hib-HepB-IPV), EasyFive-TITM (DTwP-Hib-HepB), EasyFour-TI (DTwP-Hib), EasyFourPol (DTwP-IPV) and Bivalent oral polio vaccine (type-1 and type-3). Its pipeline vaccines include NucoVac 11, DengiALL and Td (tetanus and diphtheria - reduced). Its pharmaceutical formulation products include Sitcom Tablets and Sitcom Cream. Its nutrition product brand names include ChilRun full, ChilRun 7+ and ChilRun full NoSucrose.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- PANACEABIO
- BSE Code
- 531349
Questions
Stock FAQ
What is the symbol and ISIN of Panacea Biotec?
Panacea Biotec has the symbol PANACEABIO and ISIN - INE922B01023.
What is the current price of Panacea Biotec?
Panacea Biotec is currently trading at INR 398.00.
What are the year high and year low of Panacea Biotec?
Panacea Biotec has a year high of INR 647.00 and a year low of INR 292.40.
What is the market capitalization of Panacea Biotec?
Panacea Biotec has a market capitalization of INR 2,811.95 crore.
What is the P/E ratio of Panacea Biotec?
Panacea Biotec has a P/E ratio of NA.
What is the dividend yield of Panacea Biotec?
Panacea Biotec has a dividend yield of 0.00%.
How is the financial performance of Panacea Biotec based on revenue, net income, and EPS?
Panacea Biotec has revenue of INR 639.77 crore, net income of INR -5.37 crore, and EPS of INR -2.91.
What is the book value of Panacea Biotec?
Panacea Biotec has a book value of INR 127.99.
What is the debt-to-equity ratio of Panacea Biotec?
Panacea Biotec has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Panacea Biotec?
Panacea Biotec has a price-to-book ratio of 3.11 and a price-to-sales ratio of 4.40.
Corporate-action adjustment is provider-defined. ShareKeyX research and computed indicators are not investment advice.